These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 38157806)
1. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program. Passiglia F; Lucia Reale M; Lo Russo G; Pasello G; Minuti G; Bulotta A; Galetta D; Pelizzari G; Sini C; Bria E; Roca E; Pilotto S; Genova C; Metro G; Citarella F; Chiari R; Cortinovis D; Delmonte A; Russo A; Tiseo M; Cerea G; Carta A; Scotti V; Vavalà T; Brambilla M; Buffoni L; Buosi R; Catania C; Gori S; Grisanti S; Agustoni F; Garbo E; Malapelle U; Novello S Lung Cancer; 2024 Jan; 187():107444. PubMed ID: 38157806 [TBL] [Abstract][Full Text] [Related]
2. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun. Bungaro M; Novello S; Passiglia F Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791 [TBL] [Abstract][Full Text] [Related]
3. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany. Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774 [TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. Waterhouse DM; Rothschild S; Dooms C; Mennecier B; Bozorgmehr F; Majem M; van den Heuvel MH; Linardou H; Chul Cho B; Roberts-Thomson R; Tanaka K; Blais N; Schvartsman G; Holmskov Hansen K; Chmielewska I; Forster MD; Giannopoulou C; Stollenwerk B; Obiozor CC; Wang Y; Novello S Lung Cancer; 2024 Oct; 196():107921. PubMed ID: 39303400 [TBL] [Abstract][Full Text] [Related]
5. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer. Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727 [TBL] [Abstract][Full Text] [Related]
6. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L; Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316 [TBL] [Abstract][Full Text] [Related]
7. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer. Lee A Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377 [TBL] [Abstract][Full Text] [Related]
8. Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced Thummalapalli R; Bernstein E; Herzberg B; Li BT; Iqbal A; Preeshagul I; Santini FC; Eng J; Ladanyi M; Yang SR; Shen R; Lito P; Riely GJ; Sabari JK; Arbour KC JCO Precis Oncol; 2023 Jun; 7():e2300030. PubMed ID: 37384866 [TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated Dy GK; Govindan R; Velcheti V; Falchook GS; Italiano A; Wolf J; Sacher AG; Takahashi T; Ramalingam SS; Dooms C; Kim DW; Addeo A; Desai J; Schuler M; Tomasini P; Hong DS; Lito P; Tran Q; Jones S; Anderson A; Hindoyan A; Snyder W; Skoulidis F; Li BT J Clin Oncol; 2023 Jun; 41(18):3311-3317. PubMed ID: 37098232 [No Abstract] [Full Text] [Related]
11. Sotorasib for Lung Cancers with Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690 [TBL] [Abstract][Full Text] [Related]
12. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193 [TBL] [Abstract][Full Text] [Related]
13. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. Bauml JM; Li BT; Velcheti V; Govindan R; Curioni-Fontecedro A; Dooms C; Takahashi T; Duda AW; Odegaard JI; Cruz-Guilloty F; Jin L; Zhang Y; Anderson A; Skoulidis F Lung Cancer; 2022 Apr; 166():270-278. PubMed ID: 34838325 [TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and outcomes in KRAS Barghout SH; Zhan LJ; Raptis S; Al-Agha F; Esfahanian N; Popovacki A; Kasymjanova G; Proulx-Rocray F; Chan SWS; Richardson M; Brown MC; Patel D; Dean ML; Navani V; Moore E; Carvery L; Yan E; Goldshtein D; Cleary-Gosine J; Gibson AJ; Hubley L; Balaratnam K; Ngo T; Gill A; Black M; Sacher A; Bradbury PA; Shepherd FA; Leighl N; Cheema P; Kuruvilla S; Agulnik J; Banerji S; Juergens R; Blais N; Cheung W; Wheatley-Price P; Liu G; Snow S Lung Cancer; 2024 Aug; 194():107898. PubMed ID: 39074423 [TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC. Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582 [TBL] [Abstract][Full Text] [Related]
16. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC). Parums DV Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327 [TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS Ernst SM; van Marion R; Atmodimedjo PN; de Jonge E; Mathijssen RHJ; Paats MS; de Bruijn P; Koolen SL; von der Thüsen JH; Aerts JGJV; van Schaik RHN; Dubbink HJ; Dingemans AC J Thorac Oncol; 2024 Jul; 19(7):995-1006. PubMed ID: 38615940 [TBL] [Abstract][Full Text] [Related]
18. KRAS Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176 [TBL] [Abstract][Full Text] [Related]
19. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation. Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531 [TBL] [Abstract][Full Text] [Related]
20. [Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital]. Bessy C; Blin T; Pichon E; Marchand-Adam S; Carmier D Rev Mal Respir; 2023 Jan; 40(1):17-23. PubMed ID: 36566134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]